A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal ...
About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...
A new AHA scientific statement warns that cardiovascular disease is rising fastest among younger women, with stroke rates in ...
The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...
Joint AASLD/IDSA practice recommendations reflect new data on prevention, treatment, and surveillance of chronic hepatitis B, ...
Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms ...
Thirty years after its discovery, scientists are eyeing leptin with renewed interest, for everything from weight loss drug ...
An interim review finds discrimination, staffing gaps, and poor facilities continue to undermine NHS maternity care in England.
The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.
A peer navigator intervention following a nonfatal opioid overdose in the emergency department does not significantly reduce ...
Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.
Walk-in appointments can reduce the time to pediatric dermatology visits for both atopic dermatitis and hidradenitis suppurativa and reduce ED visits for atopic dermatitis, a study finds.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results